
ProKidney Corp. (NASDAQ:PROK – Free Report) – Equities researchers at HC Wainwright cut their FY2026 earnings estimates for ProKidney in a research note issued to investors on Friday, November 13th. HC Wainwright analyst J. Pantginis now expects that the company will earn ($0.63) per share for the year, down from their previous estimate of ($0.52). The consensus estimate for ProKidney’s current full-year earnings is ($0.57) per share. HC Wainwright also issued estimates for ProKidney’s Q4 2026 earnings at ($0.16) EPS, FY2027 earnings at ($0.59) EPS, FY2028 earnings at ($0.58) EPS and FY2029 earnings at ($0.42) EPS.
ProKidney (NASDAQ:PROK – Get Free Report) last announced its earnings results on Thursday, November 12th. The company reported ($0.17) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.01). The company had revenue of $0.17 million for the quarter, compared to analyst estimates of $0.12 million.
View Our Latest Stock Analysis on ProKidney
ProKidney Price Performance
PROK stock opened at $1.04 on Tuesday. ProKidney has a one year low of $0.87 and a one year high of $2.65. The firm has a 50 day simple moving average of $1.48 and a two-hundred day simple moving average of $1.75.
Hedge Funds Weigh In On ProKidney
Institutional investors have recently modified their holdings of the company. Russell Investments Group Ltd. lifted its stake in shares of ProKidney by 163.8% in the 3rd quarter. Russell Investments Group Ltd. now owns 15,958 shares of the company’s stock valued at $26,000 after acquiring an additional 9,908 shares during the last quarter. SummitTX Capital L.P. bought a new position in ProKidney during the 1st quarter worth approximately $26,000. Cetera Investment Advisers bought a new position in ProKidney during the 3rd quarter worth approximately $27,000. StoneX Group Inc. bought a new position in ProKidney during the 3rd quarter worth approximately $30,000. Finally, Amundi increased its stake in ProKidney by 7.2% in the 1st quarter. Amundi now owns 291,708 shares of the company’s stock worth $522,000 after purchasing an additional 19,466 shares during the period. 51.59% of the stock is currently owned by institutional investors.
About ProKidney
ProKidney is a clinical-stage biotechnology company developing cell therapies for people with chronic kidney disease. The company’s work focuses on treatments intended to help preserve kidney function, particularly in patients with diabetic kidney disease. Its lead investigational product, REACT (REnal Autologous Cell Therapy), is made from cells collected from a patient’s own kidney tissue. The cells are processed and delivered back to the patient’s kidney. REACT is being evaluated in clinical trials and is not an approved treatment.
Read More
- Five stocks we like better than ProKidney
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
- Viking’s Low-Water Miss Looks Like a Buy-the-Dip Opportunity
- Why Amazon Wants the Chips and Blackstone Wants the Buildings
Receive News & Ratings for ProKidney Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProKidney and related companies with MarketBeat.com's FREE daily email newsletter.
